EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 174 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 1.00 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $143,000 | -23.1% | 3,100 | 0.0% | 0.01% | -16.7% |
| Q4 2019 | $186,000 | +8.8% | 3,100 | +2.3% | 0.01% | -14.3% |
| Q3 2019 | $171,000 | -3.4% | 3,030 | -4.7% | 0.01% | -41.7% |
| Q2 2019 | $177,000 | +9.9% | 3,180 | 0.0% | 0.01% | +9.1% |
| Q1 2019 | $161,000 | +25.8% | 3,180 | 0.0% | 0.01% | +37.5% |
| Q4 2018 | $128,000 | -28.1% | 3,180 | +35.3% | 0.01% | -11.1% |
| Q2 2018 | $178,000 | -33.1% | 2,350 | -53.6% | 0.01% | -30.8% |
| Q1 2018 | $266,000 | -1.5% | 5,060 | 0.0% | 0.01% | -7.1% |
| Q4 2017 | $270,000 | +41.4% | 5,060 | +57.6% | 0.01% | +40.0% |
| Q3 2017 | $191,000 | +26.5% | 3,210 | +68.1% | 0.01% | +25.0% |
| Q2 2017 | $151,000 | +2.0% | 1,910 | +6.7% | 0.01% | +14.3% |
| Q1 2017 | $148,000 | +2.8% | 1,790 | -1.6% | 0.01% | 0.0% |
| Q4 2016 | $144,000 | – | 1,820 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |